Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults
暂无分享,去创建一个
P. Whorwell | J. Mclaughlin | Y. Yiannakou | J. Gregson | A. Kemppinen | V. Allgar | C. Knowles | C. Howell | M. Dodd | Preeti N. Pandya | E. Markaryan
[1] Publisher'sNote , 2019, Management Accounting Research.
[2] S. Mikhalovsky,et al. Investigation of the adsorption capacity of the enterosorbent Enterosgel for a range of bacterial toxins, bile acids and pharmaceutical drugs , 2019, Scientific reports.
[3] A. Kemppinen,et al. Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial , 2019, BMJ open gastroenterology.
[4] D. S. Ahmed,et al. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome , 2018, BMC Gastroenterology.
[5] Publisher's Note , 2018, Anaesthesia.
[6] W. Chey,et al. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use , 2017, The American Journal of Gastroenterology.
[7] Tao-Tao Liu,et al. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[8] Javier Santos,et al. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome , 2017, Journal of gastroenterology and hepatology.
[9] R. Spiller. Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment , 2016, F1000Research.
[10] Lin Chang,et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. , 2016, Gastroenterology.
[11] R. Spiller,et al. Bowel Disorders. , 2016, Gastroenterology.
[12] J. West,et al. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment , 2015, PharmacoEconomics.
[13] M. El-Salhy. Recent developments in the pathophysiology of irritable bowel syndrome. , 2015, World journal of gastroenterology.
[14] Jacob E. Kurlander,et al. Irritable bowel syndrome: a clinical review. , 2015, JAMA.
[15] N. Lonardo,et al. Ventricular Tachycardia Associated with High‐Dose Chronic Loperamide Use , 2015, Pharmacotherapy.
[16] L. Saha. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. , 2014, World journal of gastroenterology.
[17] M. Pimentel,et al. Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome , 2014, Journal of neurogastroenterology and motility.
[18] Joe West,et al. The epidemiology of irritable bowel syndrome , 2014, Clinical epidemiology.
[19] I. Hall,et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea , 2013, Gut.
[20] C. Olano,et al. Management of irritable bowel syndrome in primary care , 2013 .
[21] A. Ford,et al. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[22] K. Olden. Targeted therapies for diarrhea-predominant irritable bowel syndrome , 2012, Clinical and experimental gastroenterology.
[23] J. Tack,et al. Randomised clinical trial: the safety and efficacy of AST‐120 in non‐constipating irritable bowel syndrome – a double‐blind, placebo‐controlled study , 2011, Alimentary pharmacology & therapeutics.
[24] A. Ford,et al. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents , 2011, Therapeutic advances in gastroenterology.
[25] L. Öhman,et al. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions , 2010, Nature Reviews Gastroenterology &Hepatology.
[26] D. Drossman,et al. Functional Bowel Disorders , 1995, The American Journal of Gastroenterology.
[27] F. Guarner,et al. Irritable bowel syndrome : a global perspective. , 2009 .
[28] Chih‐Yen Chen,et al. Efficacy of dioctahedral smectite in treating patients of diarrhea‐predominant irritable bowel syndrome , 2007, Journal of gastroenterology and hepatology.
[29] R Jones,et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management , 2007, Gut.
[30] A. Lowry. International Foundation for Functional Gastrointestinal Disorders , 2006 .
[31] S. Sullivan,et al. Total costs of IBS: employer and managed care perspective. , 2005, The American journal of managed care.
[32] M. Heyman,et al. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha. , 1997, Gut.